Andrew Kenneth Williams Powell's most recent trade in Aclaris Therapeutics Inc was a trade of 4,660 Common Stock done . Disclosure was reported to the exchange on June 1, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,660 | 33,523 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,660 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Purchase of securities on an exchange or from another person at price $ 1.23 per share. | 01 Mar 2024 | 8,500 | 22,863 (0%) | 0% | 1.2 | 10,455 | Common Stock |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Purchase of securities on an exchange or from another person at price $ 1.25 per share. | 01 Mar 2024 | 6,000 | 28,863 (0%) | 0% | 1.3 | 7,500 | Common Stock |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 15,750 | 15,750 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 4,660 | 4,660 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2023 | 4,507 | 14,363 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2023 | 4,507 | 0 | - | - | Restricted Stock Units | |
| Lifecore Biomedical Inc | Andrew Kenneth Williams Powell | Director | Grant, award, or other acquisition of securities at price $ 9.50 per share. | 04 Jun 2022 | 7,059 | 27,477 (0%) | 0% | 9.5 | 67,061 | Common Stock |
| Lifecore Biomedical Inc | Andrew Kenneth Williams Powell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2022 | 7,059 | 0 | - | - | Restricted Stock Unit | |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 15,750 | 15,750 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 4,507 | 4,507 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 3,356 | 13,856 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 3,356 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Andrew Kenneth Williams Powell | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Jun 2022 | 709 | 10,500 (0%) | 0% | 0 | Common Stock | |
| Lifecore Biomedical Inc | Andrew Kenneth Williams Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2022 | 9,474 | 9,474 | - | - | Restricted Stock Unit | |
| Lifecore Biomedical Inc | Andrew Kenneth Williams Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 7,059 | 7,059 | - | - | Restricted Stock Unit | |
| Lifecore Biomedical Inc | Andrew Kenneth Williams Powell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2021 | 8,303 | 0 | - | - | Restricted Stock Unit | |
| Lifecore Biomedical Inc | Andrew Kenneth Williams Powell | Director | Grant, award, or other acquisition of securities at price $ 11.64 per share. | 01 Jun 2021 | 8,303 | 20,418 (0%) | 0% | 11.6 | 96,647 | Common Stock |
| Lifecore Biomedical Inc | Andrew Kenneth Williams Powell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2020 | 2,200 | 0 | - | - | Restricted Stock Unit | |
| Lifecore Biomedical Inc | Andrew Kenneth Williams Powell | Director | Grant, award, or other acquisition of securities at price $ 10.36 per share. | 15 Oct 2020 | 2,200 | 12,115 (0%) | 0% | 10.4 | 22,792 | Common Stock |